NATIONAL BUDGET IMPACT ANALYSIS OF INTRODUCING COMBINED TRIPLE THERAPY (BUDESONIDE/ GLYCOPYRRONIUM/ FORMOTEROL FUMARATE) TO THE REIMBURSEMENT LIST FOR THE TREATMENT OF MODERATE-TO-SEVERE COPD IN ALGERIA
Author(s)
FADIA DJEBBAR, Pharmacy student1, Asma Lyna Fernane, Pharmacy student2, Abdelhakim Boudis, Professor3, Rouina Abdelaziz, Sr., Market Access manager4.
1University of health sciences - Faculty of Pharmacy, ALGIERS, Algeria, 2University of health sciences - Faculty of Pharmacy, Algiers, Algeria, 3Algerian Federation of Pharmacy, Algiers, Algeria, 4AstraZeneca Algeria, Algiers, Algeria.
1University of health sciences - Faculty of Pharmacy, ALGIERS, Algeria, 2University of health sciences - Faculty of Pharmacy, Algiers, Algeria, 3Algerian Federation of Pharmacy, Algiers, Algeria, 4AstraZeneca Algeria, Algiers, Algeria.
OBJECTIVES: In Algeria, COPD affects approximately 3.1 million people (prevalence: 6.55%). Management of moderate-to-severe forms relies on dual therapy combining a LABA with an ICS or a LAMA. For patients with persistent symptoms under dual therapy, triple therapy is recommended by GOLD guidelines, either as an open combination (LABA/ICS + LAMA) or as a fixed-dose combination (budesonide/glycopyrronium/formoterol fumarate, BGF) in a single device. This option involves higher costs than standard treatments, which can significantly influence healthcare resource utilization, in a context where COPD already represents a substantial economic burden, notably due to exacerbations. This study evaluates the budget impact of introducing BGF fixed triple therapy for moderate-to-severe COPD in Algeria.
METHODS: A budget impact analysis was conducted over a 5-year horizon (2026-2030) from the Algerian public payer perspective. The target population comprised 555,095 patients eligible for triple therapy in 2026. Clinical practice data were collected from 54 pulmonologists working in the public and private sectors, while economic data were obtained from hospital and retail pharmacies and relevant institutions, including the Ministry of Health and social security organizations. Two scenarios were compared: current practice versus one incorporating BGF, whose uptake rose from 10% in 2026 to 50% in 2030. Costs covered drug acquisition and hospitalized and outpatient exacerbations.
RESULTS: Over five years, introducing BGF would reduce total management costs from 585.7 DZD billion (€3.80 billion) to 582.6 DZD billion (€3.79 billion), a cumulative saving of 3.02 DZD billion (€32.7 million), representing 0.5% of total expenditure. The mean net impact was 3 956 DZD (€25.85)per patient per year, driven by reduced moderate-to-severe exacerbations, which lower hospitalization and outpatient costs.
CONCLUSIONS: Based on the model's assumptions, introducing BGF could reduce COPD management costs over five years, supporting its integration into national guidelines and reimbursement by Algerian social security organizations.
METHODS: A budget impact analysis was conducted over a 5-year horizon (2026-2030) from the Algerian public payer perspective. The target population comprised 555,095 patients eligible for triple therapy in 2026. Clinical practice data were collected from 54 pulmonologists working in the public and private sectors, while economic data were obtained from hospital and retail pharmacies and relevant institutions, including the Ministry of Health and social security organizations. Two scenarios were compared: current practice versus one incorporating BGF, whose uptake rose from 10% in 2026 to 50% in 2030. Costs covered drug acquisition and hospitalized and outpatient exacerbations.
RESULTS: Over five years, introducing BGF would reduce total management costs from 585.7 DZD billion (€3.80 billion) to 582.6 DZD billion (€3.79 billion), a cumulative saving of 3.02 DZD billion (€32.7 million), representing 0.5% of total expenditure. The mean net impact was 3 956 DZD (€25.85)per patient per year, driven by reduced moderate-to-severe exacerbations, which lower hospitalization and outpatient costs.
CONCLUSIONS: Based on the model's assumptions, introducing BGF could reduce COPD management costs over five years, supporting its integration into national guidelines and reimbursement by Algerian social security organizations.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE420
Topic
Economic Evaluation, Epidemiology & Public Health, Health Policy & Regulatory
Topic Subcategory
Budget Impact Analysis
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)